Tuesday 1 November 2016

NEJM Week of 13th October, 2016 (#64)

Professor Brian Andrews NEJM Recommendations for Medical Students and Tutors
Week of 13th October 2016 (#64)
University of Notre Dame Australia (Fremantle Campus)



Occasional Editorial Comment


In this week’s Journal there is a series of articles which will lead to further discussion on the treatment of malignancies which are detected in an early phase because of advances in technology. They also explore the inability to predict, at this stage of our medical ignorance, which of these tumours will possibly kill the patient before they die from other comorbidities.

This has been a problem with asymptomatic patients with prostate cancer diagnosed by an elevated PSA and a subsequent confirmatory biopsy. An attempt to answer the question of treatment options has been addressed in a serious of articles in the current issue of the Journal.

Also this issue of the Journal has an article describing the overdiagnosis of breast cancer and how this form of cancer might be managed in the future.

Screening for lung cancer using low-dose CT to monitor those who “continue to smoke” is also mentioned, but I digress.

In a previous issue of the blog (#56) a similar issue was raised for thyroid cancer (http://www.nejm.org/doi/full/10.1056/NEJMp1604412 ).



Must Read Articles


Perspective

Hard Time or Hospital Treatment? Mental Illness and the Criminal Justice System


When a mentally ill person comes into contact with the criminal justice system, the decision about whether that person belongs in jail or in the hospital is rarely a clinical one. But it may shape the course of the person's life for many years to come.

This Perspective describes the totally different outcomes when a psychotic individual arrested by police is taken to either a jail or to a hospital (in Providence RI). This study give us all pause to reflect on how this applies to Australia, particularly within the Aboriginal community.


MEDICINE AND SOCIETY

Liberty versus Need — Our Struggle to Care for People with Serious Mental Illness


Of 9.8 million U.S. adults with serious mental illness, an estimated 40% receive no treatment in any given year, often with dire consequences. But the structural impediments to care can’t be addressed without reconciling the conflicting ideals underlying them.

This is a must read, compassionate, and evidence-based article which addresses serious mental illness in the US, though equally transferable to Australia. The article outlines the ethical issues involved in treating patients who deny they have a treatable mental illness and reject treatment. This situation is particularly difficult when their future deterioration if untreated is predictable. There is also a section on medical illness and the adverse effects of anti-psychotic drugs in patients with serious mental illness.

I particularly enjoyed reading the final section entitled, “Good and Compassionate Care,” which argues that there should be a middle ground between coercion and persuasion.
 I quote: a University of Southern California law professor who was in high school when she had her first episode of schizophrenia-induced psychosis, offers nuanced analyses of coercion, judgment impairment, and ethical, legal, and medical considerations. Although she is generally protective of autonomy, she advocates a one-time autonomy violation for forced treatment “the first time a person comes to the attention of treaters in a psychotic state.” She also supports a controversial approach called Ulysses grants, whereby people sign agreements when they’re relatively well to receive psychiatric treatment when they have a psychotic episode, overriding any future refusal of care. The latter is really an advanced directive for future psychiatric care.

The article is provocative yet balanced and offers an excellent vehicle to discuss these ethical issues.


Perspective

Hearing without Listening


Computers put patient data at our fingertips, but medical teams hypnotized by their screens may not have the true intellectual interchange that lets them wrap their minds around patients' problems. Yet there are ways to turn computers from our masters into our servants.

My wife correctly points out that I hear without listening.  Thus I cannot but wonder how much of this process applies to the swarms of medical care professionals with or without their WOWs (workshops on wheels) flying from patient to patient on hospital ward rounds.



Articles Recommended for Medical Students



ORIGINAL ARTICLE

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer


In the ProtecT trial, over 1600 men with PSA-detected localized prostate cancer were assigned to active monitoring, prostatectomy, or radiotherapy. Although more patients assigned to active monitoring had disease progression, overall survival was similar in the three groups.



ORIGINAL ARTICLE

Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer


The choice of treatment for PSA-detected, localized prostate cancer is influenced by effects of the interventions on quality of life. In the ProtecT trial, patterns of side-effect severity, improvement, and decline in urinary, sexual, and bowel function differed among the treatments.


EDITORIAL

Treatment or Monitoring for Early Prostate Cancer


These two articles and the Editorial provide the most current information on managing prostate cancer patients found to have an elevated PSA on screening with biopsy proven cancer (Gleason score of 6-7 in 98% of patients).  1643 patients from the UK were randomized equally into groups for active monitoring, radical prostatectomy (robotic prostatectomy was not performed), or radiotherapy with or without 3-6 months of androgen-suppressive therapy.

 A summary of the results and reasonable recommendations (similar to current Australian recommendations) are presented in the Editorial:
1.     For today, we can conclude on the basis of level 1 evidence that PSA monitoring, as compared with treatment of early prostate cancer, leads to increased metastasis.
2.     If a man wishes to avoid metastatic prostate cancer and the side effects of its treatment, monitoring should be considered only if he has life-shortening coexisting disease such that his life expectancy is less than the 10-year median follow-up of the current study.
3.     Given no significant difference in death due to prostate cancer with surgery versus radiation and short-course androgen-deprivation therapy, men with low-risk or intermediate-risk prostate cancer should feel free to select a treatment approach using the data on health-related quality of life and without fear of possibly selecting a less effective cancer therapy.

After considering the data from the study and the adverse effects of each procedure, my personal selection at this stage would be radiotherapy. However as robotic radical prostatectomy was not employed in this study, I predict in the future that, with fewer long-term adverse results by experienced operators, robotic prostatectomy may well become a clear first choice.



IMAGES IN CLINICAL MEDICINE

Congenital Rubella


An 8-month-old child was brought to the clinic by his parents, who reported that he had had white opacities and “shaky” eyes since 4 months of age. On examination, the child had wandering eye movements with bilateral central, dense, white, nuclear congenital cataracts.

Bilateral cataract surgery in this 8 months old child led to significant functional improvement.


IMAGES IN CLINICAL MEDICINE

Reversible Acute Mesenteric Ischemia


A 60-year-old man presented with abdominal pain and hypotension. He had recently had thrombosis of the superior mesenteric artery; CT showed jejunal dilatation and thinning of the bowel wall. Videos show mucosal gangrene, hemorrhage, and healing.

This is an example of successful conservative medical management of a patient with mucosal necrosis and GI bleeding from acute mesenteric ischaemia in a situation where no further surgical or radiological intervention was possible.


CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL

Case 31-2016 — A 53-Year-Old Man with Diplopia, Polydipsia, and Polyuria


A 53-year-old man was seen in outpatient clinics of this hospital because of a 1-year history of diplopia, polydipsia, and polyuria. Imaging studies showed mucosal thickening of the sphenoid sinus and enlargement of the pituitary gland. A diagnostic procedure was performed.

IgG4-related disease is an uncommon cause of hypophysitis.

 An excellent discussion of the causes of sellar and suprasellar masses is presented.



ORIGINAL ARTICLE
Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness


This study showed that after implementation of mammography screening, the increase in the incidence of small lesions exceeded the decline in the incidence of large lesions, which implied that many of the small tumors were unlikely to become large lesions had they not been detected.


EDITORIAL

Solving the Problem of Overdiagnosis


 As indicated above in the Occasional Editorial Comment, the question will be what to do with small (? overdiagnosed) breast cancers
.
 I cannot imagine a situation currently in which a woman with a small breast cancer (definite histological diagnosis) would elect for watchful waiting rather than, at a minimum, lumpectomy with clear margins considering the low morbidity and adverse effects associated with the procedure (significantly less than radical prostatectomy or thyroidectomy).

The Editorial should be read as it discusses screening and the factors involved in overdiagnosis.

Recommended learning: Review screening as a public health method for prevention of malignant and non-malignant (e.g. lipids and bone density) conditions based on current Australian guidelines.



Important Articles Related to Mechanisms of Disease and Translational Research


CLINICAL IMPLICATIONS OF BASIC RESEARCH

Modulating Immunity to Treat Autoimmune Disease


A recent study involving a mouse model showed that a genetically tweaked T cell can specifically target the effector B cell that causes pemphigus vulgaris.

Rather than remove all CD20+ B cells with an anti-CD20 monoclonal antibody (Rituximab), which is effective in patients with pemphigus vulgaris associated with autoantibodies directed against desmoglein 3 (Dsg3), the author describes the work of Ellebrecht et al (Science 2016) which describes the use of an engineered T cell in mice capable of selectively removing only the pathogenic autoreactive B cells.  This T cell expresses a chimeric autoantibody receptor whose extracellular domain has been swapped with desmoglein 3. This Dsg3 bearing T cell recognises Dsg3-specific B cells through binding to the B-cell receptor destroying the cell with perforins and cytotoxins.



Other Articles which should interest medical students



ORIGINAL ARTICLE

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection


Ebola virus causes a devastating clinical illness that is associated with high mortality. In this trial conducted primarily in West Africa during an outbreak, ZMapp (a cocktail of three monoclonal antibodies against Ebola) showed some clinical activity.

Seventy one patients with Ebola infection were randomly assigned into two treatment groups.  One received the current standard of care alone. The other received current standard of care together with a triple monoclonal antibody cocktail against Ebola virus (ZMapp). The mortality rate at 28 days for the group receiving ZMapp was 22%, while for the other was 37%. Although it was apparent that the group receiving ZMapp had a lower mortality rate, the result did not meet the prespecified statistical threshold for efficacy.



New Pharmacological Therapies


None


Other articles which may be of interest to certain students



REVIEW ARTICLE

Cardiovascular Toxic Effects of Targeted Cancer Therapies


Agents targeting signaling pathways in cancer cells are less specific than advertised. A number of these agents induce cardiovascular toxic effects ranging from decreased ejection fraction to atrial arrhythmias.

This review article describes the basis for the new medical subspecialty of cardio-oncology (see Figures 1, 2. Table 1 indicates that virtually all current cancer therapy has the potential for cardiotoxicity).